Xencor IncNASDAQ:XNCR
- LAST PRICE19.4800
- TODAY'S CHANGE (%)0.0200 (0.1028%)
- Bid / Lots19.0700/ 10
- Ask / Lots19.6700/ 10
- Open / Previous Close19.1700 / 19.4600
- Day Range
- 52 Week Range
- Volume290,923
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XNCR |
|---|---|---|
| 09:32 ET | 5218 | 19.17 |
| 09:34 ET | 1079 | 19.175 |
| 09:36 ET | 300 | 19.09 |
| 09:38 ET | 400 | 19.205 |
| 09:41 ET | 100 | 19.31 |
| 09:45 ET | 1605 | 19.38 |
| 09:48 ET | 600 | 19.38 |
| 09:50 ET | 1631 | 19.37 |
| 09:52 ET | 3195 | 19.33 |
| 09:54 ET | 700 | 19.34 |
| 09:56 ET | 3100 | 19.4 |
| 09:59 ET | 100 | 19.27 |
| 10:01 ET | 470 | 19.325 |
| 10:03 ET | 100 | 19.32 |
| 10:06 ET | 100 | 19.38 |
| 10:08 ET | 806 | 19.5 |
| 10:10 ET | 100 | 19.61 |
| 10:12 ET | 100 | 19.56 |
| 10:14 ET | 1000 | 19.5 |
| 10:15 ET | 200 | 19.48 |
| 10:19 ET | 100 | 19.33 |
| 10:26 ET | 633 | 19.37 |
| 10:32 ET | 600 | 19.3175 |
| 10:33 ET | 820 | 19.34 |
| 10:35 ET | 200 | 19.33 |
| 10:39 ET | 800 | 19.39 |
| 10:42 ET | 1436 | 19.325 |
| 10:44 ET | 300 | 19.27 |
| 10:46 ET | 100 | 19.23 |
| 10:48 ET | 100 | 19.23 |
| 10:50 ET | 578 | 19.24 |
| 10:51 ET | 100 | 19.2 |
| 11:00 ET | 200 | 19.25 |
| 11:11 ET | 100 | 19.28 |
| 11:15 ET | 200 | 19.25 |
| 11:18 ET | 200 | 19.27 |
| 11:26 ET | 100 | 19.27 |
| 11:27 ET | 325 | 19.3 |
| 11:29 ET | 100 | 19.31 |
| 11:31 ET | 300 | 19.31 |
| 11:33 ET | 100 | 19.34 |
| 11:36 ET | 100 | 19.34 |
| 11:38 ET | 200 | 19.36 |
| 11:40 ET | 1058 | 19.3 |
| 11:42 ET | 600 | 19.355 |
| 11:47 ET | 100 | 19.39 |
| 12:00 ET | 641 | 19.35 |
| 12:03 ET | 200 | 19.34 |
| 12:05 ET | 100 | 19.4 |
| 12:07 ET | 492 | 19.43 |
| 12:09 ET | 200 | 19.46 |
| 12:14 ET | 200 | 19.45 |
| 12:16 ET | 400 | 19.53 |
| 12:18 ET | 1000 | 19.51 |
| 12:23 ET | 100 | 19.54 |
| 12:25 ET | 100 | 19.57 |
| 12:30 ET | 700 | 19.61 |
| 12:32 ET | 100 | 19.59 |
| 12:34 ET | 1400 | 19.535 |
| 12:36 ET | 100 | 19.58 |
| 12:38 ET | 500 | 19.55 |
| 12:41 ET | 168 | 19.5364 |
| 12:43 ET | 100 | 19.57 |
| 12:45 ET | 732 | 19.535 |
| 12:48 ET | 700 | 19.455 |
| 12:50 ET | 100 | 19.4775 |
| 12:52 ET | 400 | 19.425 |
| 12:54 ET | 400 | 19.4 |
| 12:56 ET | 200 | 19.39 |
| 12:57 ET | 399 | 19.41 |
| 12:59 ET | 700 | 19.4 |
| 01:01 ET | 400 | 19.39 |
| 01:03 ET | 100 | 19.4 |
| 01:12 ET | 700 | 19.38 |
| 01:17 ET | 100 | 19.38 |
| 01:19 ET | 238 | 19.42 |
| 01:21 ET | 100 | 19.42 |
| 01:24 ET | 100 | 19.45 |
| 01:28 ET | 2108 | 19.55 |
| 01:30 ET | 200 | 19.505 |
| 01:32 ET | 900 | 19.4 |
| 01:39 ET | 2416 | 19.35 |
| 01:42 ET | 300 | 19.37 |
| 01:44 ET | 4669 | 19.405 |
| 01:46 ET | 200 | 19.42 |
| 01:50 ET | 402 | 19.44 |
| 01:51 ET | 100 | 19.45 |
| 01:55 ET | 100 | 19.42 |
| 02:06 ET | 100 | 19.45 |
| 02:09 ET | 957 | 19.49 |
| 02:11 ET | 200 | 19.51 |
| 02:13 ET | 100 | 19.54 |
| 02:15 ET | 748 | 19.53 |
| 02:18 ET | 300 | 19.525 |
| 02:20 ET | 300 | 19.525 |
| 02:22 ET | 900 | 19.525 |
| 02:24 ET | 2475 | 19.48 |
| 02:26 ET | 300 | 19.48 |
| 02:27 ET | 423 | 19.54 |
| 02:33 ET | 534 | 19.47 |
| 02:42 ET | 300 | 19.47 |
| 02:44 ET | 100 | 19.47 |
| 02:45 ET | 100 | 19.47 |
| 02:47 ET | 100 | 19.45 |
| 02:49 ET | 100 | 19.425 |
| 02:51 ET | 100 | 19.46 |
| 02:56 ET | 100 | 19.46 |
| 02:58 ET | 200 | 19.46 |
| 03:00 ET | 2031 | 19.375 |
| 03:02 ET | 1416 | 19.38 |
| 03:03 ET | 200 | 19.385 |
| 03:05 ET | 500 | 19.39 |
| 03:07 ET | 100 | 19.37 |
| 03:09 ET | 100 | 19.3925 |
| 03:12 ET | 400 | 19.385 |
| 03:16 ET | 100 | 19.37 |
| 03:18 ET | 506 | 19.39 |
| 03:20 ET | 700 | 19.42 |
| 03:21 ET | 200 | 19.395 |
| 03:25 ET | 1185 | 19.39 |
| 03:30 ET | 1600 | 19.37 |
| 03:32 ET | 100 | 19.42 |
| 03:34 ET | 100 | 19.4 |
| 03:36 ET | 1006 | 19.42 |
| 03:38 ET | 286 | 19.42 |
| 03:39 ET | 1266 | 19.38 |
| 03:41 ET | 800 | 19.36 |
| 03:43 ET | 930 | 19.345 |
| 03:45 ET | 1800 | 19.34 |
| 03:48 ET | 1200 | 19.35 |
| 03:50 ET | 1100 | 19.37 |
| 03:52 ET | 3009 | 19.335 |
| 03:54 ET | 4938 | 19.41 |
| 03:56 ET | 1200 | 19.41 |
| 03:57 ET | 5444 | 19.395 |
| 03:59 ET | 64842 | 19.48 |
Sep 26, 2024
DJ Xencor Is Maintained at Outperform by RBC Capital, from 11:04AM ET on Thursday Sep 26, 2024 by Dow Jones
11:04AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 12, 2024
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 4:01PM ET on Thursday Sep 12, 2024 by Dow Jones
4:01PM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 11, 2024
DJ Xencor Shares Climb on $175 Million Offering, from 10:22AM ET on Wednesday Sep 11, 2024 by Dow Jones
10:22AM ET on Wednesday Sep 11, 2024 by Dow JonesXencor Announces Pricing of $175 Million Public Offering of Common Stock, from 6:31AM ET on Wednesday Sep 11, 2024 by Dow Jones
6:31AM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 10, 2024
Xencor Announces Proposed Public Offering of Common Stock, from 4:01PM ET on Tuesday Sep 10, 2024 by Dow Jones
4:01PM ET on Tuesday Sep 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xencor Inc | 1.4B | -6.7x | --- |
Arcus Biosciences Inc | 1.4B | -4.9x | --- |
Aurinia Pharmaceuticals Inc | 1.0B | -20.0x | --- |
WAVE Life Sciences Ltd | 1.3B | -14.7x | --- |
Travere Therapeutics Inc | 1.1B | -2.7x | --- |
Dynavax Technologies Corp | 1.5B | 110.7x | --- |
Company Information
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Contact Information
- Headquarters
- 465 N. HALSTEAD ST., SUITE 200PASADENA, CA, United States 91107
- Phone
- 626-305-5900
- Fax
- 626-305-0350
Executives
- President, Chief Executive Officer, Founder and Director
- Bassil Dahiyat
- Senior Vice President, Chief Financial Officer
- Bart Cornelissen
- Executive Vice President - Research, Chief Scientific Officer
- John Desjarlais
- Executive Vice President, Chief Development Officer
- Nancy Valente
- Senior Vice President, General Counsel, Corporate Secretary
- Celia Eckert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $133.6M |
Shares Outstanding | 69.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-2.90 |
Book Value | $10.96 |
P/E Ratio | -6.7x |
Price/Sales (TTM) | 10.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -145.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
